SI1708790T1 - Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders - Google Patents

Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders

Info

Publication number
SI1708790T1
SI1708790T1 SI200431439T SI200431439T SI1708790T1 SI 1708790 T1 SI1708790 T1 SI 1708790T1 SI 200431439 T SI200431439 T SI 200431439T SI 200431439 T SI200431439 T SI 200431439T SI 1708790 T1 SI1708790 T1 SI 1708790T1
Authority
SI
Slovenia
Prior art keywords
antagonist
dopamin
pipamperone
serotonin
treatment
Prior art date
Application number
SI200431439T
Other languages
Slovenian (sl)
Inventor
Erik Buntinx
Original Assignee
Pharmaneuroboost N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/725,965 external-priority patent/US7884096B2/en
Priority claimed from EP03447279A external-priority patent/EP1547650A1/en
Priority claimed from CA2451798A external-priority patent/CA2451798C/en
Priority claimed from US10/752,423 external-priority patent/US7855195B2/en
Priority claimed from CA 2461248 external-priority patent/CA2461248C/en
Priority claimed from US10/803,793 external-priority patent/US20050119249A1/en
Priority claimed from EP04447066A external-priority patent/EP1576985A1/en
Priority claimed from EP04025035A external-priority patent/EP1541197B8/en
Priority claimed from US10/984,683 external-priority patent/US20050203130A1/en
Priority claimed from CA 2487529 external-priority patent/CA2487529A1/en
Application filed by Pharmaneuroboost N V filed Critical Pharmaneuroboost N V
Priority claimed from EP04801138A external-priority patent/EP1708790B1/en
Publication of SI1708790T1 publication Critical patent/SI1708790T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200431439T 2003-12-02 2004-12-02 Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders SI1708790T1 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
EP03447279A EP1547650A1 (en) 2003-12-02 2003-12-02 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2451798A CA2451798C (en) 2003-12-02 2003-12-02 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US10/725,965 US7884096B2 (en) 2003-12-02 2003-12-02 Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04447001 2004-01-05
US10/752,423 US7855195B2 (en) 2003-12-02 2004-01-06 Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA 2461248 CA2461248C (en) 2003-12-02 2004-03-18 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US10/803,793 US20050119249A1 (en) 2003-12-02 2004-03-18 Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04447066A EP1576985A1 (en) 2004-03-18 2004-03-18 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04025035A EP1541197B8 (en) 2003-12-02 2004-10-21 Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders
JP2004349085A JP4571485B2 (en) 2003-12-02 2004-11-04 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US10/984,683 US20050203130A1 (en) 2003-12-02 2004-11-09 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA 2487529 CA2487529A1 (en) 2003-12-02 2004-11-15 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
EP04801138A EP1708790B1 (en) 2003-12-02 2004-12-02 Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
PCT/BE2004/000172 WO2005053796A1 (en) 2003-12-02 2004-12-02 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists

Publications (1)

Publication Number Publication Date
SI1708790T1 true SI1708790T1 (en) 2010-09-30

Family

ID=42134278

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431439T SI1708790T1 (en) 2003-12-02 2004-12-02 Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders

Country Status (8)

Country Link
AT (1) ATE464901T1 (en)
DE (1) DE602004026781D1 (en)
DK (1) DK1708790T3 (en)
ES (1) ES2343962T3 (en)
HR (1) HRP20100376T1 (en)
PT (1) PT1708790E (en)
RS (1) RS51331B (en)
SI (1) SI1708790T1 (en)

Also Published As

Publication number Publication date
HRP20100376T1 (en) 2010-08-31
DK1708790T3 (en) 2010-06-21
PT1708790E (en) 2010-07-09
ES2343962T3 (en) 2010-08-13
DE602004026781D1 (en) 2010-06-02
ATE464901T1 (en) 2010-05-15
RS51331B (en) 2011-02-28

Similar Documents

Publication Publication Date Title
PL1708790T3 (en) Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
ZA200509542B (en) Combination of an NDMA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
HK1079203A1 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
IL166058A0 (en) Novel thiophenylglycoside derivatives methods for production thereof medicaments comprising said compounds and use thereof
GB0215853D0 (en) Summarisation representation apparatus
IL169336A0 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
PL374006A1 (en) Treatment involving dkk-1 or antagonists thereof
EP1638565A4 (en) Substituted piperidine compounds and methods of their use
EP1527196A4 (en) Treatment for asthma or allergies
SI1487828T1 (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
AU2003210730A8 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
HUP0301551A3 (en) New use of 5ht3 and neuronal nicotinicreceptor antagonist 1-amino-alkycyclohexanes
PL370449A1 (en) Therapeutic acridone and acridine compounds
PL367214A1 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
GB0207410D0 (en) Compounds and their therapeutic use
IL158632A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
EP1812009A4 (en) Gaba-steroid antagonists and their use for the treatment of cns disorders
SI1708790T1 (en) Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
PT1503746E (en) Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders
PL376075A1 (en) Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists